CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 228 enrolled
Drug / intervention
Paliperidone extended-release (JNS007ER)drug
Likely dose
Paliperidone extended-release (JNS007ER) 12 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01561898
NCT01561898Phase 3Completed
CompareCT.gov

A Long-Term Study of JNS007ER in Patients With Schizophrenia

Janssen Pharmaceutical K.K.·interventional·Posted Mar 23, 2012·Updated Sep 28, 2012

In Brief

A Phase 3 clinical trial evaluating Paliperidone extended-release (JNS007ER) for Schizophrenia. Completed, enrolled 228 participants.

Detailed Summary

The purpose of this study is to assess the safety of JNS007ER 3-12 mg once daily in patients with schizophrenia over a long term period.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 23, 2012
Enrollment StartJun 1, 2006
Primary CompletionOct 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 14.3 years ago

Interventions

Paliperidone extended-release (JNS007ER)drug

Type= range, unit= mg, number= 3-12, form= tablet, route= oral use. JNS007ER within the range of 3, 6, 9 and 12 mg will be orally administered once daily for 48 weeks.